摘要
药物涂附支架解决了抑制血管成形术后再狭窄靶部位有效药物浓度和药物作用时间问题 ,具有代表性的药物涂附支架包括雷帕霉素支架、Taxol支架和肝素涂层支架 ,以及一氧化氮及其衍生物涂层支架和水蛭素涂层支架等。雷帕霉素支架和Taxol支架的动物和临床研究获得了较好实验结果。药物涂层支架防治再狭窄的长期效果尚需通过严格设计的动物实验和随机、双盲、安慰剂对照的大规模临床研究才能作出客观评价。
出处
《心脏杂志》
CAS
2004年第5期476-479,共4页
Chinese Heart Journal
参考文献24
-
1Morice M, Serruys P, sousa J, et al. The RAVEL study: a randomized study with the sirolimus coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesious[abstract] [J]. Eur Heart J, 2001,22(suppl):484
-
2Liistro F, Stankovic G, Di Mario C, et al. First clinical experience with a paclitaxel derivate- eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome[J]. Circulation,2002,105(16):1883
-
3Gregory CR, Huie P, Billingham ME, et al. Rapamycin inhibits arterial intimal thickening caused by both alloimmuoe and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels[J]. Transplantation, 1993, 55:1409-14
-
4Atsumoto Y, Shimokawa H, Morishige K, et al. Reduction in neointimal formation with a stent coated with multiple layers of releasable heparin in porcine coronary arteries[J]. J Cardiovasc Pharmacol, 2002,39(4):513-522.
-
5Alt E, Haehnel I, Beilharz C, et al. Inhibition of neointima formation after experimental coranary artery stenting: a new biodegradable stent coating releasing hirudin and prostacyclin analogue iloprost[J]. Circulation, 2000,101(12):1453-1458.
-
6Sousa JE, Costa MA, Abizaid A, et al. Lack of neoinfimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-imensional intrarascular ultrasound study[J]. Circulation, 2001,
-
7Sousa JE, Costa MA, Abizaid A, et al. Mid-(4 months) and long-term (1 year) QCA and three-dimensional IVUS follow-up after inplantation of sirolimus- coated stents in human coronary arteries[abstract][J]. J Am Coll Cardiol, 2001,37:8A.
-
8Rensing B, Vos J, Smits P, et al. Coronary restenosis elimination with a sirolimus eluting stent. First European human experience with six month angiographic and intrarascular ultrasonic follow-up[J]. Eur Heart J, 2001,22:2125-2130.
-
9Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis[J]. Circulation, 2001,103(18):2289-2295.
-
10Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent[J]. Circulation, 2001,104(4):473-479.
同被引文献35
-
1张莉莉,贾国良,王海昌,郭文怡,马兰香,孙玉波.抗血小板药物对冠心病支架植入术后再狭窄防治效果的观察[J].心脏杂志,2004,16(5):459-461. 被引量:9
-
2Weaver WD, Simes R J, Ellis SG, et al. Comparison of primary coronary angiophlasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review [ J ] .JAMA, 1997.228:2093.
-
3Stone GW,Grines BR, rothboaum D, et al. Analysis of the relativecosts and effectiveness of primary angioplastic bersus tissue - type plasminogen actibator: the primary angioplasty in myocardial infarction(PAMI) Trial[J] .JAM Coll Cardiol. 1997,29:901.
-
4Braunwald 陈灏珠主译.心脏病学[M](第5版)[M].北京:人民卫生出版社,2001.1237-1247.
-
5Grech ED.ABC of interventional cardiology:percutaneous coronary intervention.Ⅰ:history and development.BMJ 2003;326(7398):1080-1082
-
6Fischman DL,Leon MB,Baim DS,et al.A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease.Stent Restenosis Study Investigators.N Engl J Med 1994;331(8):496-501
-
7Eisenberg MJ,Konnyu KJ.Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis.Am J Cardiol 2006;98(3):375-382
-
8Yan BP,Ajani AE,Waksman R.Drug-eluting stents for the treatment of in-stent restenosis:a clinical review.Cardiovasc Revasc Med 2005;6(1):38-43
-
9Nakatani M,Takeyama Y,Shibata M,et al.Mechanisms of restenosis after coronary intervention:difference between plain old balloon angioplasty and stenting.Cardiovasc Pathol 2003;12(1):40-48
-
10Kornowski R,Hong MK,Tio FO,et al.In-stent restenosis:contributions of inflammatory responses and arterial injury to neointimal hyperplasia.J Am Coll Cardiol 1998;31(1):224-230
引证文献4
-
1岳强,李莉,赵瑞平.冠脉内支架置入术治疗急性心肌梗死48例临床观察[J].内蒙古医学杂志,2005,37(9):785-786.
-
2岳强,李莉,赵瑞平,崔丽芳.冠脉内支架置入术治疗急性心肌梗死30例[J].心脏杂志,2006,18(1):117-117.
-
3刁繁荣,吕安林,张薇,李军杰,张荣庆,苑媛,胡小菁,胡艳.雷帕霉素-替罗非班复合药物涂层支架的血液及组织相容性[J].中国组织工程研究与临床康复,2007,11(13):2411-2414.
-
4刁繁荣,吕安林,李军杰,宋延彬,温俊娜,孟晓雪.雷帕霉素-替罗非班复合药物涂层支架预防支架内血栓和再狭窄的实验研究[J].心脏杂志,2007,19(4):384-387. 被引量:13
二级引证文献13
-
1王新刚,陈明,郑博,彭红玉,张晓燕,霍勇.低剂量氯吡格雷在冠状动脉再狭窄家猪模型中应用的初步探讨[J].中国医学前沿杂志(电子版),2011,3(6):45-48.
-
2卫丽,李学奇,金恩泽,王晓云.冠脉内注射替罗非班治疗急性冠脉综合征介入术后无复流的有效性和安全性[J].心脏杂志,2009,21(1):66-68. 被引量:10
-
3何峥.心血管支架材料生物相容性的系统评价[J].中国组织工程研究与临床康复,2009,13(25):4923-4926. 被引量:2
-
4何亚磊,黄新平,孙琳.替罗非班对冠脉介入中慢血流及无复流的疗效观察[J].大理学院学报(综合版),2009,8(12):49-51. 被引量:7
-
5刘明新,王守力,陶贵周.冠状动脉支架置入后支架内的血栓问题:形成的因素及其防治[J].中国组织工程研究与临床康复,2010,14(9):1689-1692. 被引量:5
-
6龙腾河,廖明壮,罗焕江,董刚志.冠状动脉支架材料类型与置入后的效果评价[J].中国组织工程研究与临床康复,2010,14(25):4725-4728. 被引量:5
-
7张艳,李乐雯,钟书辉,贝筝,习隽丽.冠状动脉支架涂层材料对置入后发生血管再狭窄的影响[J].中国组织工程研究与临床康复,2010,14(34):6405-6408. 被引量:4
-
8罗康华,许向东.冠状动脉支架表面涂层材料对置入效果的影响[J].中国组织工程研究与临床康复,2010,14(42):7927-7930. 被引量:2
-
9张海燕,邬伟魁,贺娅,李芳,郑琴,杨明.支架血栓症及其中药防治研究[J].中国实验方剂学杂志,2011,17(22):250-256. 被引量:2
-
10刘晓峰.冠状动脉药物涂层支架与置入后的血管再狭窄[J].中国组织工程研究与临床康复,2011,15(42):7939-7942. 被引量:6
-
1孙沛霖,朱杰.干扰素治疗慢性乙型肝炎的疗效评价[J].中国公共卫生管理,2001,17(3):217-217.
-
2薛瑞璐.BUMA支架在老年急性心肌梗死急诊PCI中的应用研究[J].世界最新医学信息文摘,2016,0(38):74-74.
-
3曹赋.肺部病灶直接注药治疗复治肺结核176例疗效观察[J].中国社区医师(医学专业),2012,14(11):139-139.
-
4■藤文雄,周吉海,徐杨.日本大规模老年高血压干预试验[J].日本医学介绍,2006,27(5):219-221.
-
5那开宪,余平,郑自慧.血脂异常的诊治[J].中国临床医生杂志,2001,29(4):16-18. 被引量:9
-
6薛玉梅,吴书林.抗心律失常药物治疗进展[J].中国处方药,2006,5(7):10-13. 被引量:12
-
7监管[J].中国处方药,2009,8(12):12-12.
-
8第三届全国室性心律失常专题会议通知[J].中国心脏起搏与心电生理杂志,2010,24(6):482-482.
-
9李春雷,李竹琴,王岚峰.伊伐布雷定在心血管疾病中的研究进展[J].心血管病学进展,2012,33(3):327-330. 被引量:9
-
10第二届全国室性心律失常专题会议第一轮会议通知[J].中国微循环,2009,13(4):283-283.